IART240920P15000
- 0.25
- 0.000.00%
Integra Lifesciences Newsroom
Should We Be Cautious About Integra LifeSciences Holdings Corporation's (NASDAQ:IART) ROE Of 1.5%?
Integra LifeSciences Holdings (NASDAQ:IART) Stock Falls 9.0% in Past Week as Three-year Earnings and Shareholder Returns Continue Downward Trend
Wells Fargo Downgrades Integra Lifesciences(IART.US) to Hold Rating, Cuts Target Price to $25
Wells Fargo analyst Vik Chopra downgrades $Integra Lifesciences(IART.US)$ to a hold rating, and adjusts the target price from $45 to $25.According to TipRanks data, the analyst has a success rate of 1
Integra Lifesciences: Hold Rating Amidst Compliance Challenges and Revenue Impact With a Long-Term Recovery Outlook
Integra LifeSciences to Present at the 2024 Wells Fargo Healthcare Conference
BTIG Maintains Integra Lifesciences(IART.US) With Sell Rating, Maintains Target Price $20
BTIG analyst Ryan Zimmerman maintains $Integra Lifesciences(IART.US)$ with a sell rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 48.2%
BTIG Sticks to Their Sell Rating for Integra Lifesciences (IART)
BTIG Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $20
BTIG analyst Ryan Zimmerman maintains $Integra Lifesciences(IART.US)$ with a sell rating, and adjusts the target price from $22 to $20.According to TipRanks data, the analyst has a success rate of 48.
Bullish Integra LifeSciences Holdings Insiders Loaded Up On US$2.50m Of Stock
Integra LifeSciences Is Maintained at Sell by Citigroup
Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts
Express News | Integra Lifesciences Holdings Corp : Citigroup Cuts Target Price to $20 From $23
Citi Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $20
Citi analyst Joanne Wuensch maintains $Integra Lifesciences(IART.US)$ with a sell rating, and adjusts the target price from $23 to $20.According to TipRanks data, the analyst has a success rate of 63.
Integra LifeSciences Continues to Make Progress on Its ESG Strategy
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Potentially Undervalued?
Integra LifeSciences Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Integra's (IART) Q2 Earnings and Revenues Top, Margins Down
Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results
Integra LifeSciences Is Maintained at Market Outperform by JMP Securities
Morgan Stanley Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $25
Morgan Stanley analyst Drew Ranieri maintains $Integra Lifesciences(IART.US)$ with a sell rating, and adjusts the target price from $27 to $25.According to TipRanks data, the analyst has a success